{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:19Z","timestamp":1793155759213,"version":"4.5.0"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41574-025-01128-6","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T09:55:41Z","timestamp":1750154141000},"page":"608-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Type 1 diabetes mellitus prevention: present and future"],"prefix":"10.1038","volume":"21","author":[{"given":"Francisca L.","family":"Henriques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-3509","authenticated-orcid":false,"given":"Irina","family":"Buckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1128_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","volume":"10","author":"GA Gregory","year":"2022","unstructured":"Gregory, G. A. et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 10, 741\u2013760 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1128_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603\u2013613 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1503\/cmaj.060244","volume":"175","author":"KM Gillespie","year":"2006","unstructured":"Gillespie, K. M. Type 1 diabetes: pathogenesis and prevention. Can. Med. Assoc. J.\u00a0175, 165\u2013170 (2006).","journal-title":"Can. Med. Assoc. J."},{"key":"1128_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0140-6736(19)32127-0","volume":"394","author":"CM Dayan","year":"2019","unstructured":"Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N. & Herold, K. C. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394, 1286\u20131296 (2019).","journal-title":"Lancet"},{"key":"1128_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/dme.12676","volume":"32","author":"JA McKnight","year":"2015","unstructured":"McKnight, J. A. et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet. Med. 32, 1036\u20131050 (2015).","journal-title":"Diabet. Med."},{"key":"1128_CR6","doi-asserted-by":"publisher","first-page":"109083","DOI":"10.1016\/j.diabres.2021.109083","volume":"183","author":"GD Ogle","year":"2022","unstructured":"Ogle, G. D. et al. Global estimates of incidence of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res. Clin. Pract. 183, 109083 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1128_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41574-023-00849-w","volume":"19","author":"C Speake","year":"2023","unstructured":"Speake, C. & Greenbaum, C. J. Approval of teplizumab: implications for patients. Nat. Rev. Endocrinol. 19, 377\u2013378 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1128_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88786-4","volume":"11","author":"JM Forbes","year":"2021","unstructured":"Forbes, J. M. et al. Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. Sci. Rep. 11, 9422 (2021).","journal-title":"Sci. Rep."},{"key":"1128_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/med.21654","volume":"40","author":"S Le Bagge","year":"2020","unstructured":"Le Bagge, S., Fotheringham, A. K., Leung, S. S. & Forbes, J. M. Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. Med. Res. Rev. 40, 1200\u20131219 (2020).","journal-title":"Med. Res. Rev."},{"key":"1128_CR10","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2337\/db22-0177","volume":"71","author":"SS Leung","year":"2022","unstructured":"Leung, S. S. et al. Soluble RAGE prevents type 1 diabetes expanding functional regulatory T cells. Diabetes 71, 1994\u20132008 (2022).","journal-title":"Diabetes"},{"key":"1128_CR11","doi-asserted-by":"publisher","first-page":"152643","DOI":"10.1016\/j.prp.2019.152643","volume":"215","author":"AS Chhipa","year":"2019","unstructured":"Chhipa, A. S., Borse, S. P., Baksi, R., Lalotra, S. & Nivsarkar, M. Targeting receptors of advanced glycation end products (RAGE): preventing diabetes induced cancer and diabetic complications. Pathol. Res. Pract. 215, 152643 (2019).","journal-title":"Pathol. Res. Pract."},{"key":"1128_CR12","unstructured":"Magliano, D. J. & Boyko, E. J. IDF Diabetes Atlas (International Diabetes Federation, 2021)."},{"key":"1128_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/pedi.12296","volume":"17","author":"GD Ogle","year":"2016","unstructured":"Ogle, G. D., Middlehurst, A. C. & Silink, M. The IDF life for a child program index of diabetes care for children and youth. Pediatr. Diabetes 17, 374\u2013384 (2016).","journal-title":"Pediatr. Diabetes"},{"key":"1128_CR14","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee 2. Diagnosis and classification of diabetes: standards of care in diabetes \u2013 2024. Diabetes Care 47, S20\u2013S42 (2024).","journal-title":"Diabetes Care"},{"key":"1128_CR15","unstructured":"JDRF Australia. Economic cost of type 1 diabetes in Australia. Accenture https:\/\/breakthrought1d.org.au\/app\/uploads\/2025\/03\/The-economic-cost-of-T1D.pdf (2021)."},{"key":"1128_CR16","first-page":"311","volume":"26","author":"VN Joish","year":"2020","unstructured":"Joish, V. N. et al. Estimation of annual health care costs for adults with type 1 diabetes in the United States. J. Manag. Care Spec. Pharm. 26, 311\u2013318 (2020).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"1128_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","volume":"392","author":"A Rawshani","year":"2018","unstructured":"Rawshani, A. et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 392, 477\u2013486 (2018).","journal-title":"Lancet"},{"key":"1128_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2014.16425","volume":"313","author":"SJ Livingstone","year":"2015","unstructured":"Livingstone, S. J. et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 313, 37\u201344 (2015).","journal-title":"JAMA"},{"key":"1128_CR19","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","volume":"387","author":"M Rewers","year":"2016","unstructured":"Rewers, M. & Ludvigsson, J. Environmental risk factors for type 1 diabetes. Lancet 387, 2340\u20132348 (2016).","journal-title":"Lancet"},{"key":"1128_CR20","doi-asserted-by":"publisher","first-page":"a007690","DOI":"10.1101\/cshperspect.a007690","volume":"2","author":"M Knip","year":"2012","unstructured":"Knip, M. & Simell, O. Environmental triggers of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007690 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1128_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1399-5448.2011.00774.x","volume":"12","author":"WA Hagopian","year":"2011","unstructured":"Hagopian, W. A. et al. The environmental determinants of diabetes in the young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr. Diabetes 12, 733\u2013743 (2011).","journal-title":"Pediatr. Diabetes"},{"key":"1128_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1447.062","volume":"1150","author":"TEDDY study group","year":"2008","unstructured":"TEDDY study group The environmental determinants of diabetes in the young (TEDDY) study. Ann. N. Y. Acad. Sci. 1150, 1\u201313 (2008).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1128_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/dme.12099","volume":"30","author":"S Eringsmark Regn\u00e9ll","year":"2013","unstructured":"Eringsmark Regn\u00e9ll, S. & Lernmark, A. The environment and the origins of islet autoimmunity and type 1 diabetes. Diabet. Med. 30, 155\u2013160 (2013).","journal-title":"Diabet. Med."},{"key":"1128_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","volume":"11","author":"JA Noble","year":"2011","unstructured":"Noble, J. A. & Valdes, A. M. Genetics of the HLA region in the prediction of type 1 diabetes. Curr. Diab Rep. 11, 533\u2013542 (2011).","journal-title":"Curr. Diab Rep."},{"key":"1128_CR25","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00125-019-4952-8","volume":"62","author":"M Turtinen","year":"2019","unstructured":"Turtinen, M., H\u00e4rk\u00f6nen, T., Parkkola, A., Ilonen, J. & Knip, M. Characteristics of familial type 1 diabetes: effects of the relationship to the affected family member on phenotype and genotype at diagnosis. Diabetologia 62, 2025\u20132039 (2019).","journal-title":"Diabetologia"},{"key":"1128_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2337\/dc18-1785","volume":"42","author":"SA Sharp","year":"2019","unstructured":"Sharp, S. A. et al. Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care 42, 200\u2013207 (2019).","journal-title":"Diabetes Care"},{"key":"1128_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106792","volume":"193","author":"C Mameli","year":"2023","unstructured":"Mameli, C. et al. Lessons and gaps in the prediction and prevention of type 1 diabetes. Pharmacol. Res. 193, 106792 (2023).","journal-title":"Pharmacol. Res."},{"key":"1128_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(74)90140-8","volume":"2","author":"GF Bottazzo","year":"1974","unstructured":"Bottazzo, G. F., Florin-Christensen, A. & Doniach, D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2, 1279\u20131283 (1974).","journal-title":"Lancet"},{"key":"1128_CR29","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964\u20131974 (2015).","journal-title":"Diabetes Care"},{"key":"1128_CR30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.immuni.2010.03.018","volume":"32","author":"AG Ziegler","year":"2010","unstructured":"Ziegler, A. G. & Nepom, G. T. Prediction and pathogenesis in type 1 diabetes. Immunity 32, 468\u2013478 (2010).","journal-title":"Immunity"},{"key":"1128_CR31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cmet.2023.06.018","volume":"35","author":"MA Atkinson","year":"2023","unstructured":"Atkinson, M. A. & Mirmira, R. G. The pathogenic \u201csymphony\u201d in type 1 diabetes: a disorder of the immune system, \u03b2 cells, and exocrine pancreas. Cell Metab. 35, 1500\u20131518 (2023).","journal-title":"Cell Metab."},{"key":"1128_CR32","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler, A. G. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309, 2473\u20132479 (2013).","journal-title":"JAMA"},{"key":"1128_CR33","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc21-2612","volume":"45","author":"JP Krischer","year":"2022","unstructured":"Krischer, J. P. et al. Predictors of the initiation of islet autoimmunity and progression to multiple autoantibodies and clinical diabetes: the TEDDY study. Diabetes Care 45, 2271\u20132281 (2022).","journal-title":"Diabetes Care"},{"key":"1128_CR34","doi-asserted-by":"publisher","first-page":"1821s","DOI":"10.3945\/ajcn.110.000646","volume":"94","author":"S Hummel","year":"2011","unstructured":"Hummel, S. & Ziegler, A. G. Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies. Am. J. Clin. Nutr. 94, 1821s\u20131823s (2011).","journal-title":"Am. J. Clin. Nutr."},{"key":"1128_CR35","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2337\/dc24-er11a","volume":"47","author":"M Phillip","year":"2024","unstructured":"Phillip, M. et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 47, 1276\u20131298 (2024).","journal-title":"Diabetes Care"},{"key":"1128_CR36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00125-019-05047-w","volume":"63","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen, L. M. et al. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia 63, 588\u2013596 (2020).","journal-title":"Diabetologia"},{"key":"1128_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tem.2021.02.001","volume":"32","author":"SK Patel","year":"2021","unstructured":"Patel, S. K., Ma, C. S., Fourlanos, S. & Greenfield, J. R. Autoantibody-negative type 1 diabetes: a neglected subtype. Trends Endocrinol. Metab. 32, 295\u2013305 (2021).","journal-title":"Trends Endocrinol. Metab."},{"key":"1128_CR38","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s00125-020-05114-7","volume":"63","author":"SJ Hanna","year":"2020","unstructured":"Hanna, S. J. et al. Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia 63, 1174\u20131185 (2020).","journal-title":"Diabetologia"},{"key":"1128_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/dc19-0747","volume":"43","author":"A Carlsson","year":"2020","unstructured":"Carlsson, A. et al. Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish national cohort study. Diabetes Care 43, 82\u201389 (2020).","journal-title":"Diabetes Care"},{"key":"1128_CR40","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","volume":"64","author":"RIG Holt","year":"2021","unstructured":"Holt, R. I. G. et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 64, 2609\u20132652 (2021).","journal-title":"Diabetologia"},{"key":"1128_CR41","unstructured":"Ogle, G. D., Wang, F., Gregory, G. A. & Maniam, J. Type 1 diabetes estimates in children and adults. International Diabetes Federation diabetesatlas.org\/media\/uploads\/sites\/3\/2025\/03\/IDF-T1D-Index-Report.pdf (2022)."},{"key":"1128_CR42","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2337\/dc21-1238","volume":"45","author":"K Herzog","year":"2021","unstructured":"Herzog, K. et al. Alterations in biomarkers related to glycemia, lipid metabolism, and inflammation up to 20 years before diagnosis of type 1 diabetes in adults: findings from the AMORIS cohort. Diabetes Care 45, 330\u2013338 (2021).","journal-title":"Diabetes Care"},{"key":"1128_CR43","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.2337\/dc22-2159","volume":"46","author":"NJ Thomas","year":"2023","unstructured":"Thomas, N. J. et al. Age of diagnosis does not alter the presentation or progression of robustly defined adult-onset type 1 diabetes. Diabetes Care 46, 1156\u20131163 (2023).","journal-title":"Diabetes Care"},{"key":"1128_CR44","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/nature08933","volume":"464","author":"JA Bluestone","year":"2010","unstructured":"Bluestone, J. A., Herold, K. & Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464, 1293\u20131300 (2010).","journal-title":"Nature"},{"key":"1128_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0002-9343(81)90417-4","volume":"70","author":"W Gepts","year":"1981","unstructured":"Gepts, W. & Lecompte, P. M. The pancreatic islets in diabetes. Am. J. Med. 70, 105\u2013115 (1981).","journal-title":"Am. J. Med."},{"key":"1128_CR46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/BF00452061","volume":"29","author":"AK Foulis","year":"1986","unstructured":"Foulis, A. K., Liddle, C. N., Farquharson, M. A., Richmond, J. A. & Weir, R. S. The histopathology of the pancreas in type I (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29, 267\u2013274 (1986).","journal-title":"Diabetologia"},{"key":"1128_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1464-5491.1986.tb00722.x","volume":"3","author":"GF Bottazzo","year":"1986","unstructured":"Bottazzo, G. F. Lawrence lecture. death of a beta cell: homicide or suicide? Diabet. Med. 3, 119\u2013130 (1986).","journal-title":"Diabet. Med."},{"key":"1128_CR48","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.2337\/db10-1797","volume":"60","author":"MA Atkinson","year":"2011","unstructured":"Atkinson, M. A. et al. How does type 1 diabetes develop?: the notion of homicide or \u03b2-cell suicide revisited. Diabetes 60, 1370\u20131379 (2011).","journal-title":"Diabetes"},{"key":"1128_CR49","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","volume":"17","author":"BO Roep","year":"2021","unstructured":"Roep, B. O., Thomaidou, S., van Tienhoven, R. & Zaldumbide, A. Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?). Nat. Rev. Endocrinol. 17, 150\u2013161 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1128_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2337\/diab.44.3.326","volume":"44","author":"S Wong","year":"1995","unstructured":"Wong, S. et al. Expression of the co-stimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse. Diabetes 44, 326\u2013329 (1995).","journal-title":"Diabetes"},{"key":"1128_CR51","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/12465","volume":"5","author":"FS Wong","year":"1999","unstructured":"Wong, F. S. et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 5, 1026\u20131031 (1999).","journal-title":"Nat. Med."},{"key":"1128_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00125-004-1645-7","volume":"48","author":"D Klein","year":"2005","unstructured":"Klein, D. et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 48, 268\u2013276 (2005).","journal-title":"Diabetologia"},{"key":"1128_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1568-9972(03)00009-0","volume":"2","author":"P Narendran","year":"2003","unstructured":"Narendran, P., Mannering, S. I. & Harrison, L. C. Proinsulin \u2013 a pathogenic autoantigen in type 1 diabetes. Autoimmun. Rev. 2, 204\u2013210 (2003).","journal-title":"Autoimmun. Rev."},{"key":"1128_CR54","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2337\/db12-0112","volume":"61","author":"T Delong","year":"2012","unstructured":"Delong, T. et al. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes 61, 3239\u20133246 (2012).","journal-title":"Diabetes"},{"key":"1128_CR55","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.aad2791","volume":"351","author":"T Delong","year":"2016","unstructured":"Delong, T. et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351, 711\u2013714 (2016).","journal-title":"Science"},{"key":"1128_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2013.10.003","volume":"50","author":"PA Gottlieb","year":"2014","unstructured":"Gottlieb, P. A. et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J. Autoimmun. 50, 38\u201341 (2014).","journal-title":"J. Autoimmun."},{"key":"1128_CR57","doi-asserted-by":"publisher","first-page":"667870","DOI":"10.3389\/fimmu.2021.667870","volume":"12","author":"SI Mannering","year":"2021","unstructured":"Mannering, S. I., Rubin, A. F., Wang, R. & Bhattacharjee, P. Identifying new hybrid insulin peptides (HIPs) in type 1 diabetes. Front. Immunol. 12, 667870 (2021).","journal-title":"Front. Immunol."},{"key":"1128_CR58","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1073\/pnas.78.10.6456","volume":"78","author":"S Baekkeskov","year":"1981","unstructured":"Baekkeskov, S. et al. Expression of major histocompatibility antigens on pancreatic islet cells. Proc. Natl Acad. Sci. 78, 6456\u20136460 (1981).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1128_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00299027","volume":"30","author":"AK Foulis","year":"1987","unstructured":"Foulis, A. K., Farquharson, M. A. & Hardman, R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30, 333\u2013343 (1987).","journal-title":"Diabetologia"},{"key":"1128_CR60","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","volume":"59","author":"SJ Richardson","year":"2016","unstructured":"Richardson, S. J. et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59, 2448\u20132458 (2016).","journal-title":"Diabetologia"},{"key":"1128_CR61","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/db18-0686","volume":"68","author":"MA Russell","year":"2019","unstructured":"Russell, M. A. et al. HLA class II antigen processing and presentation pathway components demonstrated by transcriptome and protein analyses of islet \u03b2-cells from donors with type 1 diabetes. Diabetes 68, 988\u20131001 (2019).","journal-title":"Diabetes"},{"key":"1128_CR62","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1172\/JCI116835","volume":"92","author":"N Itoh","year":"1993","unstructured":"Itoh, N. et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Investig. 92, 2313\u20132322 (1993).","journal-title":"J. Clin. Investig."},{"key":"1128_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049213","volume":"7","author":"WW Unger","year":"2012","unstructured":"Unger, W. W. et al. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD\/scid\/IL2RG null mice. PLoS ONE 7, e49213 (2012).","journal-title":"PLoS ONE"},{"key":"1128_CR64","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/1074-7613(95)90062-4","volume":"3","author":"MG von Herrath","year":"1995","unstructured":"von Herrath, M. G., Guerder, S., Lewicki, H., Flavell, R. A. & Oldstone, M. B. Coexpression of B7-1 and viral (\u201cself\u201d) transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 3, 727\u2013738 (1995).","journal-title":"Immunity"},{"key":"1128_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/smim.1997.0108","volume":"10","author":"MG von Herrath","year":"1998","unstructured":"von Herrath, M. G., Holz, A., Homann, D. & Oldstone, M. B. Role of viruses in type I diabetes. Semin. Immunol. 10, 87\u2013100 (1998).","journal-title":"Semin. Immunol."},{"key":"1128_CR66","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.molmed.2024.06.011","volume":"30","author":"K Dahl-J\u00f8rgensen","year":"2024","unstructured":"Dahl-J\u00f8rgensen, K. Virus as the cause of type 1 diabetes. Trends Mol. Med. 30, 1020\u20131027 (2024).","journal-title":"Trends Mol. Med."},{"key":"1128_CR67","doi-asserted-by":"publisher","first-page":"a007682","DOI":"10.1101\/cshperspect.a007682","volume":"2","author":"KT Coppieters","year":"2012","unstructured":"Coppieters, K. T., Boettler, T. & von Herrath, M. Virus infections in type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007682 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1128_CR68","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ajpath.2016.11.002","volume":"187","author":"E Kuric","year":"2017","unstructured":"Kuric, E. et al. Demonstration of tissue resident memory CD8 T cells in insulitic lesions in adult patients with recent-onset type 1 diabetes. Am. J. Pathol. 187, 581\u2013588 (2017).","journal-title":"Am. J. Pathol."},{"key":"1128_CR69","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1084\/jem.20011353","volume":"196","author":"MC Gagnerault","year":"2002","unstructured":"Gagnerault, M. C., Luan, J. J., Lotton, C. & Lepault, F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J. Exp. Med. 196, 369\u2013377 (2002).","journal-title":"J. Exp. Med."},{"key":"1128_CR70","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1084\/jem.184.3.923","volume":"184","author":"C Kurts","year":"1996","unstructured":"Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923\u2013930 (1996).","journal-title":"J. Exp. Med."},{"key":"1128_CR71","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2353\/ajpath.2006.060539","volume":"169","author":"B Calderon","year":"2006","unstructured":"Calderon, B., Suri, A. & Unanue, E. R. In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model. Am. J. Pathol. 169, 2137\u20132147 (2006).","journal-title":"Am. J. Pathol."},{"key":"1128_CR72","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/cei.13353","volume":"198","author":"AM Sandor","year":"2019","unstructured":"Sandor, A. M., Jacobelli, J. & Friedman, R. S. Immune cell trafficking to the islets during type 1 diabetes. Clin. Exp. Immunol. 198, 314\u2013325 (2019).","journal-title":"Clin. Exp. Immunol."},{"key":"1128_CR73","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00125-017-4377-1","volume":"60","author":"CM Hull","year":"2017","unstructured":"Hull, C. M., Peakman, M. & Tree, T. I. M. Regulatory T cell dysfunction in type 1 diabetes: what\u2019s broken and how can we fix it? Diabetologia 60, 1839\u20131850 (2017).","journal-title":"Diabetologia"},{"key":"1128_CR74","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nri2889","volume":"10","author":"JH Buckner","year":"2010","unstructured":"Buckner, J. H. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10, 849\u2013859 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1128_CR75","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.2337\/db15-1615","volume":"65","author":"P Leete","year":"2016","unstructured":"Leete, P. et al. Differential insulitic profiles determine the extent of \u03b2-cell destruction and the age at onset of type 1 diabetes. Diabetes 65, 1362\u20131369 (2016).","journal-title":"Diabetes"},{"key":"1128_CR76","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2249.2008.03860.x","volume":"155","author":"A Willcox","year":"2009","unstructured":"Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K. & Morgan, N. G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155, 173\u2013181 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"1128_CR77","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41574-023-00853-0","volume":"19","author":"MJ Redondo","year":"2023","unstructured":"Redondo, M. J. & Morgan, N. G. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 19, 542\u2013554 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1128_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MED.0000000000000547","volume":"27","author":"MJ Smith","year":"2020","unstructured":"Smith, M. J., Cambier, J. C. & Gottlieb, P. A. Endotypes in T1D: B lymphocytes and early onset. Curr. Opin. Endocrinol. Diabetes Obes. 27, 225\u2013230 (2020).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"1128_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12943","volume":"92","author":"C Vandamme","year":"2020","unstructured":"Vandamme, C. & Kinnunen, T. B cell helper T cells and type 1 diabetes. Scand. J. Immunol. 92, e12943 (2020).","journal-title":"Scand. J. Immunol."},{"key":"1128_CR80","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.clim.2017.09.021","volume":"183","author":"P Hanley","year":"2017","unstructured":"Hanley, P. et al. Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes. Clin. Immunol. 183, 336\u2013343 (2017).","journal-title":"Clin. Immunol."},{"key":"1128_CR81","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.2337\/db11-0700","volume":"60","author":"R Mallone","year":"2011","unstructured":"Mallone, R. & Brezar, V. To B or not to B: (anti)bodies of evidence on the crime scene of type 1 diabetes? Diabetes 60, 2020\u20132022 (2011).","journal-title":"Diabetes"},{"key":"1128_CR82","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3389\/fimmu.2018.01281","volume":"9","author":"AI Pinto","year":"2018","unstructured":"Pinto, A. I., Smith, J., Kissack, M. R., Hogg, K. G. & Green, E. A. Thymic B cell-mediated attack of thymic stroma precedes type 1 diabetes development. Front. Immunol. 9, 1281 (2018).","journal-title":"Front. Immunol."},{"key":"1128_CR83","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2337\/dc20-1829","volume":"44","author":"B Karges","year":"2021","unstructured":"Karges, B. et al. A comparison of familial and sporadic type 1 diabetes among young patients. Diabetes Care 44, 1116\u20131124 (2021).","journal-title":"Diabetes Care"},{"key":"1128_CR84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/dme.12100","volume":"30","author":"JS Skyler","year":"2013","unstructured":"Skyler, J. S. Primary and secondary prevention of type 1 diabetes. Diabet. Med. 30, 161\u2013169 (2013).","journal-title":"Diabet. Med."},{"key":"1128_CR85","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/pedi.12734","volume":"19","author":"JJ Couper","year":"2018","unstructured":"Couper, J. J. et al. ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents. Pediatr. Diabetes 19, 20\u201327 (2018).","journal-title":"Pediatr. Diabetes"},{"key":"1128_CR86","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2014.06.015","volume":"437","author":"ZD Hu","year":"2014","unstructured":"Hu, Z. D. & Deng, A. M. Autoantibodies in pre-clinical autoimmune disease. Clin. Chim. Acta 437, 14\u201318 (2014).","journal-title":"Clin. Chim. Acta"},{"key":"1128_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00125-019-4822-4","volume":"62","author":"RA Oram","year":"2019","unstructured":"Oram, R. A., Sims, E. K. & Evans-Molina, C. Beta cells in type 1 diabetes: mass and function; sleeping or dead? Diabetologia 62, 567\u2013577 (2019).","journal-title":"Diabetologia"},{"key":"1128_CR88","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","volume":"53","author":"JP Palmer","year":"2004","unstructured":"Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21\u201322 October 2001. Diabetes 53, 250\u2013264 (2004).","journal-title":"Diabetes"},{"key":"1128_CR89","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/dmr.5610030410","volume":"3","author":"JS Skyler","year":"1987","unstructured":"Skyler, J. S. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 3, 1017\u20131035 (1987).","journal-title":"Diabetes Metab. Rev."},{"key":"1128_CR90","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.6367043","volume":"223","author":"CR Stiller","year":"1984","unstructured":"Stiller, C. R. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223, 1362\u20131367 (1984).","journal-title":"Science"},{"key":"1128_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","volume":"2","author":"G Feutren","year":"1986","unstructured":"Feutren, G. et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2, 119\u2013124 (1986).","journal-title":"Lancet"},{"key":"1128_CR92","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2337\/diacare.22.3.478","volume":"22","author":"HH Parving","year":"1999","unstructured":"Parving, H. H. et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 22, 478\u2013483 (1999).","journal-title":"Diabetes Care"},{"key":"1128_CR93","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1073\/pnas.91.1.123","volume":"91","author":"L Chatenoud","year":"1994","unstructured":"Chatenoud, L., Thervet, E., Primo, J. & Bach, J. F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA\u00a091, 123\u2013127 (1994).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1128_CR94","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2249.1993.tb05888.x","volume":"91","author":"F Nicoletti","year":"1993","unstructured":"Nicoletti, F. et al. Prevention of cyclophosphamide-induced diabetes in the NOD\/WEHI mouse with deoxyspergualin. Clin. Exp. Immunol. 91, 232\u2013236 (1993).","journal-title":"Clin. Exp. Immunol."},{"key":"1128_CR95","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1021\/acs.biochem.9b00707","volume":"58","author":"J Gaglia","year":"2019","unstructured":"Gaglia, J. & Kissler, S. Anti-CD3 antibody for the prevention of type 1 diabetes: a story of perseverance. Biochemistry 58, 4107\u20134111 (2019).","journal-title":"Biochemistry"},{"key":"1128_CR96","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.clim.2009.04.007","volume":"132","author":"KC Herold","year":"2009","unstructured":"Herold, K. C. et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132, 166\u2013173 (2009).","journal-title":"Clin. Immunol."},{"key":"1128_CR97","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692\u20131698 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR98","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"B Keymeulen","year":"2005","unstructured":"Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598\u20132608 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR99","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","volume":"53","author":"B Keymeulen","year":"2010","unstructured":"Keymeulen, B. et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53, 614\u2013623 (2010).","journal-title":"Diabetologia"},{"key":"1128_CR100","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.2337\/db13-0236","volume":"62","author":"W Hagopian","year":"2013","unstructured":"Hagopian, W. et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial. Diabetes 62, 3901\u20133908 (2013).","journal-title":"Diabetes"},{"key":"1128_CR101","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/dme.12361","volume":"31","author":"P Ambery","year":"2014","unstructured":"Ambery, P. et al. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet. Med. 31, 399\u2013402 (2014).","journal-title":"Diabet. Med."},{"key":"1128_CR102","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.2337\/dc13-0327","volume":"37","author":"R Aronson","year":"2014","unstructured":"Aronson, R. et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37, 2746\u20132754 (2014).","journal-title":"Diabetes Care"},{"key":"1128_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","volume":"378","author":"N Sherry","year":"2011","unstructured":"Sherry, N. et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487\u2013497 (2011).","journal-title":"Lancet"},{"key":"1128_CR104","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S2213-8587(22)00390-4","volume":"11","author":"C Evans-Molina","year":"2023","unstructured":"Evans-Molina, C. & Oram, R. A. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 11, 76\u201377 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1128_CR105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8980","volume":"13","author":"EK Sims","year":"2021","unstructured":"Sims, E. K. et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci. Transl. Med. 13, eabc8980 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1128_CR106","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos, E. L. et al. Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes. N. Engl. J. Med. 389, 2151\u20132161 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR107","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood-2009-02-204875","volume":"115","author":"B Keymeulen","year":"2010","unstructured":"Keymeulen, B. et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 115, 1145\u20131155 (2010).","journal-title":"Blood"},{"key":"1128_CR108","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00125-023-05953-0","volume":"66","author":"S Hummel","year":"2023","unstructured":"Hummel, S. et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia 66, 1633\u20131642 (2023).","journal-title":"Diabetologia"},{"key":"1128_CR109","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00125-013-2850-z","volume":"56","author":"S Fredheim","year":"2013","unstructured":"Fredheim, S. et al. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia 56, 995\u20131003 (2013).","journal-title":"Diabetologia"},{"key":"1128_CR110","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/pedi.12809","volume":"20","author":"LM Duca","year":"2019","unstructured":"Duca, L. M. et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study. Pediatr. Diabetes 20, 172\u2013179 (2019).","journal-title":"Pediatr. Diabetes"},{"key":"1128_CR111","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/dc17-0558","volume":"40","author":"LM Duca","year":"2017","unstructured":"Duca, L. M., Wang, B., Rewers, M. & Rewers, A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care 40, 1249\u20131255 (2017).","journal-title":"Diabetes Care"},{"key":"1128_CR112","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.2337\/dc13-1904","volume":"37","author":"FJ Cameron","year":"2014","unstructured":"Cameron, F. J. et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 37, 1554\u20131562 (2014).","journal-title":"Diabetes Care"},{"key":"1128_CR113","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/0145721712445216","volume":"38","author":"R Whittemore","year":"2012","unstructured":"Whittemore, R., Jaser, S., Chao, A., Jang, M. & Grey, M. Psychological experience of parents of children with type 1 diabetes: a systematic mixed-studies review. Diabetes Educ. 38, 562\u2013579 (2012).","journal-title":"Diabetes Educ."},{"key":"1128_CR114","doi-asserted-by":"publisher","first-page":"40762","DOI":"10.1074\/jbc.M110.169276","volume":"285","author":"H Park","year":"2010","unstructured":"Park, H., Adsit, F. G. & Boyington, J. C. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J. Biol. Chem. 285, 40762\u201340770 (2010).","journal-title":"J. Biol. Chem."},{"key":"1128_CR115","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","volume":"97","author":"MA Hofmann","year":"1999","unstructured":"Hofmann, M. A. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100\/calgranulin polypeptides. Cell 97, 889\u2013901 (1999).","journal-title":"Cell"},{"key":"1128_CR116","doi-asserted-by":"publisher","first-page":"25752","DOI":"10.1074\/jbc.270.43.25752","volume":"270","author":"O Hori","year":"1995","unstructured":"Hori, O. et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752\u201325761 (1995).","journal-title":"J. Biol. Chem."},{"key":"1128_CR117","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"SD Yan","year":"1996","unstructured":"Yan, S. D. et al. RAGE and amyloid-\u03b2 peptide neurotoxicity in Alzheimer\u2019s disease. Nature 382, 685\u2013691 (1996).","journal-title":"Nature"},{"key":"1128_CR118","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/labinvest.3780116","volume":"80","author":"MM Sousa","year":"2000","unstructured":"Sousa, M. M., Yan, S. D., Stern, D. & Saraiva, M. J. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab. Invest. 80, 1101\u20131110 (2000).","journal-title":"Lab. Invest."},{"key":"1128_CR119","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1084\/jem.20030800","volume":"198","author":"T Chavakis","year":"2003","unstructured":"Chavakis, T. et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198, 1507\u20131515 (2003).","journal-title":"J. Exp. Med."},{"key":"1128_CR120","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2012.02.001","volume":"274","author":"W Ma","year":"2012","unstructured":"Ma, W. et al. RAGE binds C1q and enhances C1q-mediated phagocytosis. Cell Immunol. 274, 72\u201382 (2012).","journal-title":"Cell Immunol."},{"key":"1128_CR121","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/35012626","volume":"405","author":"A Taguchi","year":"2000","unstructured":"Taguchi, A. et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354\u2013360 (2000).","journal-title":"Nature"},{"key":"1128_CR122","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2337\/diabetes.50.6.1495","volume":"50","author":"CH Yeh","year":"2001","unstructured":"Yeh, C. H. et al. Requirement for p38 and p44\/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-\u03baB transcriptional activation and cytokine secretion. Diabetes 50, 1495\u20131504 (2001).","journal-title":"Diabetes"},{"key":"1128_CR123","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1042\/BJ20120298","volume":"448","author":"S Grimm","year":"2012","unstructured":"Grimm, S. et al. Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2\/STAT1. Biochem. J. 448, 127\u2013139 (2012).","journal-title":"Biochem. J."},{"key":"1128_CR124","doi-asserted-by":"publisher","first-page":"19919","DOI":"10.1074\/jbc.274.28.19919","volume":"274","author":"HJ Huttunen","year":"1999","unstructured":"Huttunen, H. J., Fages, C. & Rauvala, H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-\u03baB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274, 19919\u201319924 (1999).","journal-title":"J. Biol. Chem."},{"key":"1128_CR125","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","volume":"2","author":"C Ott","year":"2014","unstructured":"Ott, C. et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2, 411\u2013429 (2014).","journal-title":"Redox Biol."},{"key":"1128_CR126","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.cellsig.2013.06.013","volume":"25","author":"J Xie","year":"2013","unstructured":"Xie, J., Mendez, J. D., Mendez-Valenzuela, V. & Aguilar-Hernandez, M. M. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 25, 2185\u20132197 (2013).","journal-title":"Cell Signal."},{"key":"1128_CR127","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.3390\/cells11213503","volume":"11","author":"C Du","year":"2022","unstructured":"Du, C. et al. Advanced glycation end products and inflammation in type 1 diabetes development. Cells 11, 3503 (2022).","journal-title":"Cells"},{"key":"1128_CR128","first-page":"459","volume":"71","author":"M Sakaguchi","year":"2017","unstructured":"Sakaguchi, M. et al. Signal diversity of receptor for advanced glycation end products. Acta Med. Okayama 71, 459\u2013465 (2017).","journal-title":"Acta Med. Okayama"},{"key":"1128_CR129","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11892-016-0782-y","volume":"16","author":"SS Leung","year":"2016","unstructured":"Leung, S. S., Forbes, J. M. & Borg, D. J. Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis. Curr. Diab Rep. 16, 100 (2016).","journal-title":"Curr. Diab Rep."},{"key":"1128_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39243-x","volume":"13","author":"SS Leung","year":"2023","unstructured":"Leung, S. S. et al. Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes. Sci. Rep. 13, 12948 (2023).","journal-title":"Sci. Rep."},{"key":"1128_CR131","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.4049\/jimmunol.1600197","volume":"197","author":"SP Durning","year":"2016","unstructured":"Durning, S. P. et al. The receptor for advanced glycation endproducts drives T cell survival and inflammation in type 1 diabetes mellitus. J. Immunol. 197, 3076\u20133085 (2016).","journal-title":"J. Immunol."},{"key":"1128_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034698","volume":"7","author":"EM Akirav","year":"2012","unstructured":"Akirav, E. M. et al. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS ONE 7, e34698 (2012).","journal-title":"PLoS ONE"},{"key":"1128_CR133","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.4049\/jimmunol.181.6.4272","volume":"181","author":"Y Chen","year":"2008","unstructured":"Chen, Y. et al. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181, 4272\u20134278 (2008).","journal-title":"J. Immunol."},{"key":"1128_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095678","volume":"9","author":"EM Akirav","year":"2014","unstructured":"Akirav, E. M. et al. The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma. PLoS ONE 9, e95678 (2014).","journal-title":"PLoS ONE"},{"key":"1128_CR135","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.4049\/jimmunol.179.12.8051","volume":"179","author":"B Moser","year":"2007","unstructured":"Moser, B. et al. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J. Immunol. 179, 8051\u20138058 (2007).","journal-title":"J. Immunol."},{"key":"1128_CR136","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2337\/db10-1033","volume":"60","author":"MT Coughlan","year":"2011","unstructured":"Coughlan, M. T. et al. Advanced glycation end products are direct modulators of \u03b2-cell function. Diabetes 60, 2523\u20132532 (2011).","journal-title":"Diabetes"},{"key":"1128_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109165","volume":"245","author":"AA Joshi","year":"2022","unstructured":"Joshi, A. A. et al. RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice. Clin. Immunol. 245, 109165 (2022).","journal-title":"Clin. Immunol."},{"key":"1128_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/alz.041198","volume":"16","author":"AH Burstein","year":"2020","unstructured":"Burstein, A. H., Dunn, I., Gooch, A. M. & Valcarce, C. Effects of azeliragon on ADAS-cog and CDR domains and individual items in patients with mild Alzheimer\u2019s disease and type 2 diabetes (T2D). Alzheimer\u2019s Dement. 16, e041198 (2020).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1128_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-12","volume":"14","author":"AH Burstein","year":"2014","unstructured":"Burstein, A. H. et al. Effect of TTP488 in patients with mild to moderate Alzheimer\u2019s disease. BMC Neurol. 14, 12 (2014).","journal-title":"BMC Neurol."},{"key":"1128_CR140","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2018.18","volume":"5","author":"AH Burstein","year":"2018","unstructured":"Burstein, A. H. et al. Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 5, 149\u2013154 (2018).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1128_CR141","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.4049\/jimmunol.180.4.2270","volume":"180","author":"AA Manfredi","year":"2008","unstructured":"Manfredi, A. A. et al. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 180, 2270\u20132275 (2008).","journal-title":"J. Immunol."},{"key":"1128_CR142","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1002\/art.23042","volume":"56","author":"H Wittkowski","year":"2007","unstructured":"Wittkowski, H. et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 56, 4174\u20134181 (2007).","journal-title":"Arthritis Rheum."},{"key":"1128_CR143","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM197608192950804","volume":"295","author":"RJ Koenig","year":"1976","unstructured":"Koenig, R. J. et al. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N. Engl. J. Med. 295, 417\u2013420 (1976).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR144","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0531-5565(01)00138-3","volume":"36","author":"JW Baynes","year":"2001","unstructured":"Baynes, J. W. The role of AGEs in aging: causation or correlation. Exp. Gerontol. 36, 1527\u20131537 (2001).","journal-title":"Exp. Gerontol."},{"key":"1128_CR145","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1210\/en.2008-1342","volume":"150","author":"Z Zhao","year":"2009","unstructured":"Zhao, Z. et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 150, 2569\u20132576 (2009).","journal-title":"Endocrinology"},{"key":"1128_CR146","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1681\/ASN.2008050514","volume":"20","author":"MT Coughlan","year":"2009","unstructured":"Coughlan, M. T. et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 20, 742\u2013752 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1128_CR147","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2337\/diabetes.52.6.1441","volume":"52","author":"M Peppa","year":"2003","unstructured":"Peppa, M. et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 52, 1441\u20131448 (2003).","journal-title":"Diabetes"},{"key":"1128_CR148","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1084\/jem.186.10.1663","volume":"186","author":"J Verdaguer","year":"1997","unstructured":"Verdaguer, J. et al. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J. Exp. Med. 186, 1663\u20131676 (1997).","journal-title":"J. Exp. Med."},{"key":"1128_CR149","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/19382014.2017.1405189","volume":"10","author":"DJ Borg","year":"2018","unstructured":"Borg, D. J. et al. Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. Islets 10, 10\u201324 (2018).","journal-title":"Islets"},{"key":"1128_CR150","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jnutbio.2012.09.009","volume":"24","author":"JM Forbes","year":"2013","unstructured":"Forbes, J. M. et al. Glucose homeostasis can be differentially modulated by varying individual components of a western diet. J. Nutr. Biochem. 24, 1251\u20131257 (2013).","journal-title":"J. Nutr. Biochem."},{"key":"1128_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2021.110547","volume":"147","author":"KCW van Dongen","year":"2021","unstructured":"van Dongen, K. C. W. et al. Dietary advanced glycation endproducts (AGEs) increase their concentration in plasma and tissues, result in inflammation and modulate gut microbial composition in mice; evidence for reversibility. Food Res. Int. 147, 110547 (2021).","journal-title":"Food Res. Int."},{"key":"1128_CR152","doi-asserted-by":"publisher","first-page":"eabe4841","DOI":"10.1126\/sciadv.abe4841","volume":"7","author":"M Snelson","year":"2021","unstructured":"Snelson, M. et al. Processed foods drive intestinal barrier permeability and microvascular diseases. Sci. Adv. 7, eabe4841 (2021).","journal-title":"Sci. Adv."},{"key":"1128_CR153","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2337\/db11-0971","volume":"61","author":"H Beyan","year":"2012","unstructured":"Beyan, H. et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes 61, 1192\u20131198 (2012).","journal-title":"Diabetes"},{"key":"1128_CR154","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.2337\/dc10-1058","volume":"33","author":"V Mericq","year":"2010","unstructured":"Mericq, V. et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 33, 2232\u20132237 (2010).","journal-title":"Diabetes Care"},{"key":"1128_CR155","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3945\/ajcn.115.125427","volume":"103","author":"B de Courten","year":"2016","unstructured":"de Courten, B. et al. Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. Am. J. Clin. Nutr. 103, 1426\u20131433 (2016).","journal-title":"Am. J. Clin. Nutr."},{"key":"1128_CR156","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00125-016-4053-x","volume":"59","author":"H Vlassara","year":"2016","unstructured":"Vlassara, H. et al. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia 59, 2181\u20132192 (2016).","journal-title":"Diabetologia"},{"key":"1128_CR157","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156950","volume":"7","author":"AM Linkens","year":"2022","unstructured":"Linkens, A. M. et al. A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. JCI Insight 7, e156950 (2022).","journal-title":"JCI Insight"},{"key":"1128_CR158","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1006\/geno.1994.1517","volume":"23","author":"K Sugaya","year":"1994","unstructured":"Sugaya, K. et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23, 408\u2013419 (1994).","journal-title":"Genomics"},{"key":"1128_CR159","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1006\/geno.1994.1676","volume":"24","author":"H Vissing","year":"1994","unstructured":"Vissing, H., Aagaard, L., Tommerup, N. & Boel, E. Localization of the human gene for advanced glycosylation end product-specific receptor (AGER) to chromosome 6p21.3. Genomics 24, 606\u2013608 (1994).","journal-title":"Genomics"},{"key":"1128_CR160","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2067353","volume":"2019","author":"M Serveaux-Dancer","year":"2019","unstructured":"Serveaux-Dancer, M. et al. Pathological implications of receptor for advanced glycation end-product (AGER) gene polymorphism. Dis. Markers 2019, 2067353 (2019).","journal-title":"Dis. Markers"},{"key":"1128_CR161","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2265.2011.04079.x","volume":"75","author":"W Lu","year":"2011","unstructured":"Lu, W., Feng, B., Xie, G. & Liu, F. Association of AGER gene G82S polymorphism with the severity of coronary artery disease in Chinese Han population. Clin. Endocrinol. 75, 470\u2013474 (2011).","journal-title":"Clin. Endocrinol."},{"key":"1128_CR162","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1503\/jpn.110024","volume":"37","author":"P Suchankova","year":"2012","unstructured":"Suchankova, P. et al. Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? J. Psychiatry Neurosci. 37, 122\u2013128 (2012).","journal-title":"J. Psychiatry Neurosci."},{"key":"1128_CR163","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.gene.2016.02.029","volume":"584","author":"JN Adams","year":"2016","unstructured":"Adams, J. N. et al. Genetic analysis of advanced glycation end products in the DHS MIND study. Gene 584, 173\u2013179 (2016).","journal-title":"Gene"},{"key":"1128_CR164","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.metabol.2006.09.013","volume":"56","author":"Y Jang","year":"2007","unstructured":"Jang, Y. et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56, 199\u2013205 (2007).","journal-title":"Metabolism"},{"key":"1128_CR165","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.2337\/dc13-3049","volume":"37","author":"KM Salonen","year":"2014","unstructured":"Salonen, K. M. et al. Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes. Diabetes Care 37, 1975\u20131981 (2014).","journal-title":"Diabetes Care"},{"key":"1128_CR166","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s00125-011-2058-z","volume":"54","author":"JM Forbes","year":"2011","unstructured":"Forbes, J. M. et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia 54, 1032\u20131042 (2011).","journal-title":"Diabetologia"},{"key":"1128_CR167","doi-asserted-by":"publisher","unstructured":"Salonen, K. M. et al. A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes. Diabetes Metab. Res. Rev. https:\/\/doi.org\/10.1002\/dmrr.2872 (2016).","DOI":"10.1002\/dmrr.2872"},{"key":"1128_CR168","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2337\/dc14-1186","volume":"38","author":"KM Salonen","year":"2015","unstructured":"Salonen, K. M. et al. Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes. Diabetes Care 38, 665\u2013670 (2015).","journal-title":"Diabetes Care"},{"key":"1128_CR169","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio, L. A., Evans-Molina, C. & Oram, R. A. Type 1 diabetes. Lancet 391, 2449\u20132462 (2018).","journal-title":"Lancet"},{"key":"1128_CR170","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","volume":"346","author":"Diabetes Prevention Trial\u2013Type 1 Diabetes Study Group","year":"2002","unstructured":"Diabetes Prevention Trial\u2013Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685\u20131691 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR171","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","volume":"28","author":"JS Skyler","year":"2005","unstructured":"Skyler, J. S. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial\u2013Type 1. Diabetes Care 28, 1068\u20131076 (2005).","journal-title":"Diabetes Care"},{"key":"1128_CR172","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00125-020-05376-1","volume":"64","author":"R Assfalg","year":"2021","unstructured":"Assfalg, R. et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia 64, 1079\u20131092 (2021).","journal-title":"Diabetologia"},{"key":"1128_CR173","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"JP Krischer","year":"2017","unstructured":"Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S. & Greenbaum, C. J. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318, 1891\u20131902 (2017).","journal-title":"JAMA"},{"key":"1128_CR174","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028578","volume":"9","author":"AG Ziegler","year":"2019","unstructured":"Ziegler, A. G. et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 9, e028578 (2019).","journal-title":"BMJ Open."},{"key":"1128_CR175","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011144","volume":"6","author":"J Raab","year":"2016","unstructured":"Raab, J. et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 6, e011144 (2016).","journal-title":"BMJ Open."},{"key":"1128_CR176","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","volume":"372","author":"K N\u00e4nt\u00f6-Salonen","year":"2008","unstructured":"N\u00e4nt\u00f6-Salonen, K. et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372, 1746\u20131755 (2008).","journal-title":"Lancet"},{"key":"1128_CR177","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.2337\/diacare.27.10.2348","volume":"27","author":"LC Harrison","year":"2004","unstructured":"Harrison, L. C. et al. Pancreatic \u03b2-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27, 2348\u20132355 (2004).","journal-title":"Diabetes Care"},{"key":"1128_CR178","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMc1616343","volume":"376","author":"J Ludvigsson","year":"2017","unstructured":"Ludvigsson, J., Wahlberg, J. & Casas, R. Intralymphatic injection of autoantigen in type 1 diabetes. N. Engl. J. Med. 376, 697\u2013699 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR179","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00592-022-01852-9","volume":"59","author":"R Casas","year":"2022","unstructured":"Casas, R. et al. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE extension trial). Acta Diabetol. 59, 687\u2013696 (2022).","journal-title":"Acta Diabetol."},{"key":"1128_CR180","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2337\/dc21-0318","volume":"44","author":"J Ludvigsson","year":"2021","unstructured":"Ludvigsson, J. et al. Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial. Diabetes Care 44, 1604\u20131612 (2021).","journal-title":"Diabetes Care"},{"key":"1128_CR181","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00125-020-05227-z","volume":"63","author":"U Hannelius","year":"2020","unstructured":"Hannelius, U., Beam, C. A. & Ludvigsson, J. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. Diabetologia 63, 2177\u20132181 (2020).","journal-title":"Diabetologia"},{"key":"1128_CR182","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3440","volume":"37","author":"J Ludvigsson","year":"2021","unstructured":"Ludvigsson, J. et al. Combined etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes. Diabetes\/Metab. Res. Rev. 37, e3440 (2021).","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"1128_CR183","first-page":"271","volume":"2","author":"GS Eisenbarth","year":"1985","unstructured":"Eisenbarth, G. S. et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 2, 271\u2013276 (1985).","journal-title":"Diabetes Res."},{"key":"1128_CR184","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1172\/JCI78492","volume":"125","author":"MJ Haller","year":"2015","unstructured":"Haller, M. J. et al. Anti-thymocyte globulin\/G-CSF treatment preserves \u03b2 cell function in patients with established type 1 diabetes. J. Clin. Investig. 125, 448\u2013455 (2015).","journal-title":"J. Clin. Investig."},{"key":"1128_CR185","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.2337\/db16-0823","volume":"65","author":"MJ Haller","year":"2016","unstructured":"Haller, M. J. et al. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes 65, 3765\u20133775 (2016).","journal-title":"Diabetes"},{"key":"1128_CR186","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","volume":"1","author":"SE Gitelman","year":"2013","unstructured":"Gitelman, S. E. et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 1, 306\u2013316 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1128_CR187","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","volume":"59","author":"SE Gitelman","year":"2016","unstructured":"Gitelman, S. E. et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia 59, 1153\u20131161 (2016).","journal-title":"Diabetologia"},{"key":"1128_CR188","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2337\/dc13-0604","volume":"37","author":"T Orban","year":"2014","unstructured":"Orban, T. et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37, 1069\u20131075 (2014).","journal-title":"Diabetes Care"},{"key":"1128_CR189","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412\u2013419 (2011).","journal-title":"Lancet"},{"key":"1128_CR190","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2337\/dc22-2200","volume":"46","author":"WE Russell","year":"2023","unstructured":"Russell, W. E. et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care 46, 1005\u20131013 (2023).","journal-title":"Diabetes Care"},{"key":"1128_CR191","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295\u2013305 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1128_CR192","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg, M. et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J. Autoimmun. 58, 48\u201358 (2015).","journal-title":"J. Autoimmun."},{"key":"1128_CR193","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","volume":"63","author":"M Rosenzwajg","year":"2020","unstructured":"Rosenzwajg, M. et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I\/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 63, 1808\u20131821 (2020).","journal-title":"Diabetologia"},{"key":"1128_CR194","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12688\/wellcomeopenres.15697.1","volume":"5","author":"ML Marcovecchio","year":"2020","unstructured":"Marcovecchio, M. L. et al. Interleukin-2 therapy of autoimmunity in diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial. Wellcome Open. Res. 5, 49 (2020).","journal-title":"Wellcome Open. Res."},{"key":"1128_CR195","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab022","volume":"2","author":"AK Marwaha","year":"2022","unstructured":"Marwaha, A. K. et al. A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes. Immunother. Adv. 2, ltab022 (2022).","journal-title":"Immunother. Adv."},{"key":"1128_CR196","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1038\/s41591-024-03115-2","volume":"30","author":"D Tatovic","year":"2024","unstructured":"Tatovic, D. et al. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nat. Med. 30, 2657\u20132666 (2024).","journal-title":"Nat. Med."},{"key":"1128_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02900-z","volume":"21","author":"J Van Rampelbergh","year":"2023","unstructured":"Van Rampelbergh, J. et al. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes. BMC Med. 21, 190 (2023).","journal-title":"BMC Med."},{"key":"1128_CR198","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03476-y","volume":"22","author":"J Van Rampelbergh","year":"2024","unstructured":"Van Rampelbergh, J. et al. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers. BMC Med. 22, 259 (2024).","journal-title":"BMC Med."},{"key":"1128_CR199","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/dc13-0626","volume":"37","author":"MD Pescovitz","year":"2014","unstructured":"Pescovitz, M. D. et al. B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results. Diabetes Care 37, 453\u2013459 (2014).","journal-title":"Diabetes Care"},{"key":"1128_CR200","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","volume":"361","author":"MD Pescovitz","year":"2009","unstructured":"Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143\u20132152 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR201","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/01926233221100168","volume":"50","author":"TD Flandre","year":"2022","unstructured":"Flandre, T. D., Mansfield, K. G., Espi\u00e9, P. J., Rubic-Schneider, T. & Ulrich, P. Immunosuppression profile of CFZ533 (Iscalimab), a non-depleting anti-CD40 antibody, and the presence of opportunistic infections in a rhesus monkey toxicology study. Toxicol. Pathol. 50, 712\u2013724 (2022).","journal-title":"Toxicol. Pathol."},{"key":"1128_CR202","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06356-z","volume":"23","author":"M Waibel","year":"2022","unstructured":"Waibel, M. et al. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT) \u2013 study protocol for a phase 2, randomized, placebo controlled trial. Trials 23, 433 (2022).","journal-title":"Trials"},{"key":"1128_CR203","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel, M. et al. Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N. Engl. J. Med. 389, 2140\u20132150 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1128_CR204","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1073\/pnas.0810246105","volume":"105","author":"C Louvet","year":"2008","unstructured":"Louvet, C. et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl Acad. Sci. USA\u00a0105, 18895\u201318900 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1128_CR205","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","volume":"9","author":"SE Gitelman","year":"2021","unstructured":"Gitelman, S. E. et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 502\u2013514 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1128_CR206","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","volume":"24","author":"F Ovalle","year":"2018","unstructured":"Ovalle, F. et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat. Med. 24, 1108\u20131112 (2018).","journal-title":"Nat. Med."},{"key":"1128_CR207","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2023.2064","volume":"329","author":"GP Forlenza","year":"2023","unstructured":"Forlenza, G. P. et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA 329, 990\u2013999 (2023).","journal-title":"JAMA"},{"key":"1128_CR208","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091597","volume":"14","author":"J Wych","year":"2024","unstructured":"Wych, J. et al. Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. BMJ Open. 14, e091597 (2024).","journal-title":"BMJ Open."},{"key":"1128_CR209","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","volume":"9","author":"M von Herrath","year":"2021","unstructured":"von Herrath, M. et al. Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 212\u2013224 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1128_CR210","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/db16-0806","volume":"66","author":"JS Skyler","year":"2017","unstructured":"Skyler, J. S. et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66, 241\u2013255 (2017).","journal-title":"Diabetes"},{"key":"1128_CR211","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155896","volume":"7","author":"F Jessop","year":"2022","unstructured":"Jessop, F. et al. Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice. JCI Insight 7, e155896 (2022).","journal-title":"JCI Insight"},{"key":"1128_CR212","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1172\/JCI99987","volume":"129","author":"RJ Pickering","year":"2019","unstructured":"Pickering, R. J. et al. Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J. Clin. Investig. 129, 406\u2013421 (2019).","journal-title":"J. Clin. Investig."},{"key":"1128_CR213","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/db16-1250","volume":"66","author":"PM Trivedi","year":"2017","unstructured":"Trivedi, P. M. et al. Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice. Diabetes 66, 1650\u20131660 (2017).","journal-title":"Diabetes"},{"key":"1128_CR214","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00125-017-4536-4","volume":"61","author":"A Coomans de Brach\u00e8ne","year":"2018","unstructured":"Coomans de Brach\u00e8ne, A. et al. IFN-\u03b1 induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia 61, 636\u2013640 (2018).","journal-title":"Diabetologia"},{"key":"1128_CR215","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588543","volume":"11","author":"T Ge","year":"2020","unstructured":"Ge, T. et al. The JAK1 selective inhibitor ABT 317 blocks signaling through interferon-\u03b3 and common \u03b3 chain cytokine receptors to reverse autoimmune diabetes in NOD mice. Front. Immunol. 11, 588543 (2020).","journal-title":"Front. Immunol."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01128-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:02:27Z","timestamp":1757548947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01128-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":215,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1038\/s41574-025-01128-6","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"30 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}